Expanding the high-dose influenza vaccine recommendation to include middle-aged adults with chronic health conditions may make economic sense and save lives. The findings may justify for clinical trials of the high-dose and new recombinant trivalent influenza vaccines in 50- to 64-year-old adults with chronic illnesses, such as heart or lung disease, diabetes, or cancer, to determine if they do provide considerably better protection than the currently recommended standard dose quadrivalent vaccine.
Influenza vaccination rates in children may have decreased for the 2016-17 influenza season because of a recommendation by the Centers for Disease Control and Prevention that the nasal spray version of the vaccine not be used, according to researchers.
Scientists have identified several genes and gene clusters associated with the immune response to flu vaccination. The findings point to the prospect of using genetic profiles to predict individual responses to the flu vaccine.
Cervical cancer is the second most common cause of cancer-related death worldwide, with almost 300,000 deaths occurring each year. More than 80 percent of these deaths occur in developing nations. The advent of human papillomavirus (HPV) vaccines has significantly reduced the number of those who develop and die from cervical cancer.
An international team has developed a unique computational model to project the spread of the seasonal flu in real time. It uses posts on Twitter in combination with key parameters of each season's epidemic, including the incubation period of the disease, the immunization rate, how many people an individual with the virus can infect, and the viral strains present.
The threat of a major flu pandemic is a perennial concern. Now scientists have developed a fast and easy-to-use point-of-care diagnostic test that could one day help doctors and hospitals head off the rapid spread of the flu.
According to a meta-analysis of three randomized controlled trials, zinc acetate lozenges may increase the rate of recovery from the common cold three fold. On the fifth day, 70 percent of the zinc lozenge patients had recovered compared with 27 percent of the placebo patients.
The risk of having a heart attack is 17 times higher in the seven days following a respiratory infection, research has found. The increased risk peaks in the first 7 days and gradually reduces but remains elevated for one month.
There is no vaccine. No medication. And, no quick, reliable test for Zika virus … until now. Babies born with the virus often have lifelong, devastating birth defects. Testing for the virus currently involves trained medical staff drawing and mailing blood samples to a lab, a process that can take up to four weeks. Scientists have now developed a quick, simple test for Zika virus so easy to administer, you don't even need a doctor.
Vaccinating pregnant mothers year-round against flu in the resource-challenged region of subtropical Nepal reduced infant flu virus infection rates by an average of 30 percent, increased birth weights by 15 percent and resulted in babies having less influenza, according to a study. An international research team reports expanding year-round flu vaccinations during pregnancy would also benefit children in other tropical and subtropical parts of the world.
Two randomized trials that examined the effects of zinc lozenges for the duration of common cold symptoms found that colds were shortened on average by 4.0 days and by 1.77 days. However, the shortest colds in the placebo groups of both studies lasted for only two days.
Researchers converted a staple human ubiquitin protein into an anti-viral tool. Through subtle tweaks, they created an engineered version of the ubiquitin that binds more tightly and paralyzes a key enzyme in MERS to halt viral replication in cells. Other synthetic forms of ubiquitin can be quickly generated to target a diverse range of pathogens.
Scientists have made another important advance in HIV vaccine design. The development was possible thanks to previous studies showing the structures of a protein on HIV’s surface, called the envelope glycoprotein. The scientists used these structures to design a mimic of the viral protein from a different HIV subtype, subtype C, which is responsible for the majority of infections worldwide.